Clinical trial

Effect of Oral N-Acetyl Cysteine in Prevention of Necrotizing Enterocolitis in Preterm Neonates With Feeding Intolerance

Name
Ekram Hassan
Description
necrotizing enterocolitis is a dangerous disease that may be fatal especially in preterm neonates, the early features of the disease are symptoms of feeding intolerance and interruption of the baby's feeding plan , so prophylactic measures at this stage may help to prevent its progression and its complications. N-acetyl cysteine is an FDA- approved drug and has many uses in different diseases and in different age groups including neonates, it has a mucolytic and anti-inflammatory and anti-oxidant effects that are believed to break the bacterial biofilm which enables it to stick to the intestinal wall and also decrease the intestinal wall inflammation, therefore enhance the intestinal barrier and decrease the chance of bacterial invasion.
Trial arms
Trial start
2023-01-01
Estimated PCD
2024-03-30
Trial end
2024-03-30
Status
Active (not recruiting)
Phase
Early phase I
Treatment
oral n-acetyl cysteine
the active participants will receive oral N-acetyl cysteine with dose 20mg/dose every 6 hours for 10 days or until reaching full feeding or resolution of feeding intolerance
Arms:
intervention group
placebo
the control group will receive placebo
Arms:
control group
Size
100
Primary endpoint
incidence of necrotizing enterocolitis
10 days
Eligibility criteria
Inclusion Criteria: * preterm neonates (less than or = 36 weeks gestational age ) * feeding intolerance Exclusion Criteria: * active gastro-intestinal tract bleeding * Gastro- intestinal tract surgical problem * Congenital gastro-intestinal tract anomalies * evidence of allergy to NAC * use of prebiotics or probiotics
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-01-12

1 organization

1 product

3 indications